Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL, Li XF, Dai XH, Li N, Cheng ML, Huang Z, Shen J, Ge YH, Shen ZW, Deng YQ, Yang SY, Zhao H, Zhang NN, Zhang YF, Wei L, Wu KQ, Zhu MF, Peng CG, Jiang Q, Cao SC, Li YH, Zhao DH, Wu XH, Ni L, Shen HH, Dong C, Ying B, Sheng GP, Qin CF, Gao HN, Li LJ.
Chen GL, et al. Among authors: sheng gp.
Lancet Microbe. 2022 Mar;3(3):e193-e202. doi: 10.1016/S2666-5247(21)00280-9. Epub 2022 Jan 24.
Lancet Microbe. 2022.
PMID: 35098177
Free PMC article.
Clinical Trial.